On March 6, 2024 Bristol Myers Squibb (NYSE: BMY) reported that the company will participate in two upcoming investor conferences in March 2024 (Press release, Bristol-Myers Squibb, MAR 6, 2024, View Source [SID1234640850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET.

Lynelle Hoch, president, Cell Therapy Organization, and Wendy Short Bartie, senior vice president, U.S. Hematology and Oncology, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami Beach, Florida, on Thursday, March 14, 2024. They will answer questions about the company beginning at 8:30 a.m. ET.

Investors and the general public are invited to listen to both sessions at their respective times by visiting View Source An archived edition of each session will be available following its conclusion.

On March 5, 2024 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) (Press release, Transgene, MAR 6, 2024, View Source [SID1234640809]). The AACR (Free AACR Whitepaper) will take place in San Diego, California, USA, from April 5 to 10, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster details

Title: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

· Session title: Late-Breaking Research: Clinical Research 3

· Poster and abstract number: LB401

· Date and Time: Wednesday April 10, 2024, 9:00 a.m. – 12:30 p.m. PDT

· Location: Poster Section 52, Board number 2

· Authors : A. Lalanne, C. Jamet, JP Delord, C. Ottensmeier, C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M. Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke, N. Yamagata, Y. Tanaka, K. Onoguchi, I. G. Pait, B. Malone, O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K. Bendjama, O. Lantz

The abstract will be available on the AACR (Free AACR Whitepaper) website April 5, 2024, at 3:00 p.m. ET / 9:00 p.m. CET.

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning (ML) expertise. TG4050 is being evaluated in a randomized multicenter Phase I clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024. TG4050 is being jointly developed by Transgene and NEC.

On March 5, 2024 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, reported that its management expects to participate in the following investor conferences in March (Press release, Cartesian Therapeutics, MAR 6, 2024, View Source [SID1234640806]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation at the 2024 Leerink Partners Global Biopharma Conference at 8:40 a.m. ET on Wednesday, March 13, 2024 in Miami, FL
A fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference at 11:00 a.m. ET on Tuesday, March 26, 2024

A live webcast of the presentation and fireside chat are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

On March 5, 2024 Bayer reported its annual report 2023 (Presentation, Bayer, MAR 5, 2024, View Source [SID1234642168]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 6, 2024 Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody zenocutuzumab (Zeno) for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 taking place in San Diego, CA April 5-10, 2024 (Press release, Merus, MAR 5, 2024, View Source [SID1234640874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels. High NRG1 expression is associated with poorer prognosis in certain cancers and resistance to standard therapies. The anti-tumor efficacy of Zeno in vivo against a panel of 28 patient-derived xenograft (PDX) models representing different tumor types was examined. The results show that Zeno significantly inhibited tumor growth in seven high-NRG1-expressing PDX models representing multiple different tumor types.

Presentation Details:

Title: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression.
Session Category: Experimental and Molecular Therapeutics
Session: Antibody-Drug Conjugates and Bispecific Antibodies
Date: Monday, April 8, 2024
Time: 9:00 am-12:30 p.m. PT
Location: Poster Section 23
Poster #: 14
Abstract #: 1903

The full abstract is available on the AACR (Free AACR Whitepaper) website. The poster will be available on the Merus website at the start of the session.

Zeno is being investigated in the phase 1/2 eNRGy trial and Early Access Program which are assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer. Based on recent productive and collaborative discussions with the U.S. Food & Drug Administration, we believe we will have sufficient clinical data in the first half of 2024 to support potential Biologics License Application submissions in NRG1+ non-small cell lung cancer and NRG1+ pancreatic cancer.

About Zeno
Zeno is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics that utilizes the Merus Dock & Block mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 gene fusions (NRG1+ cancer). Through its unique mechanism of binding to HER2 and potently blocking the interaction of HER3 with its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to be particularly effective against NRG1+ cancer. In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.